

Haematologica
HAEMATOL/2019/218545
Version 4

Low dose Btk inhibitors selectively block platelet activation by CLEC-2

Phillip L.R. Nicolson, Sophie H. Nock, Joshua Hinds, Lourdes Garcia-Quintanilla, Christopher W. Smith, Joana Campos, Alexander Brill, Jeremy A. Pike, Abdullah O. Khan, Natalie S. Poulter, Diedre M. Kavanagh, Stephanie Watson, Callum N. Watson, Hayley Clifford, Aarnoud P. Huissoon, Alice Y. Pollitt, Johannes A. Eble, Guy Pratt, Steve P. Watson, and Craig E. Hughes

Disclosures: This work was supported by British Heart Foundation (BHF) Programme grant (RG/13/18/30563), a BHF Clinical Fellowship to PLRN (FS/17/20/32738), a BHF Senior Basic Science Research Fellowship to AB (FS/19/30/34173), an AMS springboard grant to AYP (SBF002\1099) and the University of Birmingham's Institute of Translation Medicine and Institute of Cardiovascular Sciences; SPW holds a BHF Chair (CH03/003). JAE is supported by the Deutsche Forschungsgemeinschaft (DFG grant: Eb177/13-1). Btk deficient DT40 cells, plasmid constructs and rabbit anti-Btk antibody were a kind gift from Dr Mike Tomlinson (University of Birmingham, UK). PLR Nicolson has received research grants from Rigel Pharmaceuticals, Novartis Pharmaceuticals and materials from Principia Biopharma.

Contributions: PLRN, CEH, SHN and SPW conceived the study and wrote the manuscript. PLRN, SHN, JH, LG-Q, CWS, JC, AB, AOK, NSP, DNK, SW and CNW performed experiments. PLRN, SHN, JH and JAP performed data analysis. HC and APH consented and provided access to patients with XLA. JAE provided key reagents. GP consented and provided access to patients with CLL. CEH, AYP and SPW supervised the study. All authors critically appraised the manuscript.